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Abstract18
Immunotherapies use components of the patient immune system to selec-19
tively target cancer cells. The use of chimeric antigenic receptor (CAR) T20
cells to treat B-cell malignancies –leukaemias and lymphomas– is one of the21
most successful examples, with many patients experiencing long-lasting full22
responses to this therapy. This treatment works by extracting the patient’s23
T cells and transducing them with the CAR, enabling them to recognize24
and target cells carrying the antigen CD19+, which is expressed in these25
haematological ancers.26
Here we put forward a mathematical model describing the time response27
of leukaemias to the injection of CAR T cells. The model accounts for ma-28
ture and progenitor B-cells, leukaemic cells, CAR T cells and side effects29
by including the main biological processes involved. The model explains the30
early post-injection dynamics of the different compartments and the fact that31
the number of CAR T cells injected does not critically affect the treatment32
outcome. An explicit formula is found that gives the maximum CAR T cell33
expansion in vivo and the severity of side effects. Our mathematical model34
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captures other known features of the response to this immunotherapy. It35
also predicts that CD19+ cancer relapses could be the result of competition36
between leukaemic and CAR T cells, analogous to predator-prey dynamics.37
We discuss this in the light of the available evidence and the possibility of38
controlling relapses by early re-challenging of the leukaemia cells with stored39
CAR T cells.40
Keywords: Mathematical modelling, Cancer dynamics, Immunotherapy,41
Tumour-immune system interactions, Mathematical oncology42
1. Introduction
Cancer immunotherapy approaches use components of a patient’s own
immune system to selectively target cancer cells. Immunotherapies are al-
ready an effective treatment option for several cancers due to their selectivity,
long-lasting effects, and benefits for overall survival [1].
Chimeric antigen receptor (CAR) T cell therapy represents a major step
in personalised cancer treatment, and is the most successful type of im-
munotherapy. This therapy is predicated on the use of gene-transfer tech-
nology to instruct T lymphocytes to recognise and kill cancer cells. CARs
are synthetic receptors that mediate antigen recognition, T cell activation,
and co-stimulation to increase T cell functionality and persistence. For the
clinical application, the patient’s T cells are obtained, genetically engineered
ex vivo to express the synthetic receptor, expanded and infused back into the
patient [2].
Clinical trials have shown promising results in end-stage patients with B-
cell malignancies due to their expression of the CD19 protein [3]. CAR T cells
engineered to recognise this antigen have led to an early clinical response
of up to 92% in Acute Lymphoblastic Leukaemia (ALL) patients [4, 5, 6,
7]. Good results have been reported for large B-cell lymphomas [8, 9] and
multiple myelomas [10]. These successes have led to the approval of CAR
T therapies for use against CD19 for treatment of B-ALL and diffuse large
B-cell lymphomas [3].
CAR T-related toxicities are cytokine release syndrome (CRS), due to
the release of cytokines during CAR T cell action, and immune effector-
cell-associated neurotoxicity syndrome (ICANS). CRS symptoms including
hypotension, pulmonary oedema, multiorgan failure, and even death, are
now better controlled using IL-6 inhibitor tocilizumab [11].
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Despite the success of CAR T cell therapy seen so far, a variable fraction,
between 30% and 60%, of patients relapse after treatment. There are two dif-
ferent types of post-CAR relapse. In the first type, post-CAR leukaemic cells
show expression of the CD19+ antigen and other immunophenotypic charac-
teristics that are the same as those of the original clone. This is consistent
with the recurrence of the initial leukaemic clone. In this case, pre-CAR
and post-CAR blasts typically show the same CD19 expression levels.
This type of recurrence shows a down-regulation of the CD19 antigen [12].
In this situation, CAR T cells cannot recognise their targets and the tumour
regrows. In contrast to CD19+ recurrence, CD19− recurrence occurs despite
functional persistence of CAR T cells and ongoing B-cell aplasia [12, 13].
There are many previous studies devoted to the mathematical modelling
of tumour-immune cell interactions, see for instance [14, 15, 16, 17, 18, 19]
and references therein. Mathematical models have the potential to provide
a mechanistic understanding of oncological treatments, and may help in
finding optimised strategies to improve treatment outcome [20, 21]. This is
why CAR T cell treatments have attracted the interest of mathematicians in
the context of gliomas [22, 23], melanomas [24] and B-cell malignancies [25,
26, 27, 28, 29].
In this study, we will describe mathematically the longitudinal dynamics
of B cells, leukaemic clones and CAR T cells. The mathematical models will
be shown to provide both a mechanistic explanation for the results of differ-
ent clinical trials and formulas quantifying some of the observed phenomena.
We will discuss some implications for CD19+ relapses and how it might be
possible to control them by re-challenging the cancer early with CAR T
cells.
2. Mathematical models and parameter estimation
2.1. Basic mathematical model
Our mathematical model accounts for the evolution over time of several
interacting cellular populations distributed into five compartments. Let C(t),
L(t), B(t), P (t), and I(t) denote the non-negative time-varying functions
representing the number of CAR T cells, leukaemic cells, mature healthy B
cells, CD19− haematopoietic stem cells (HSCs), and CD19+ B cell progen-
itors (i.e. Pre-B, Pro-B and immature bone marrow B cells), respectively.
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Our initial autonomous system of differential equations is as follows:
dC
dt
= ρC (L+B)C + ρβIC − 1
τC
C, (1a)
dL
dt
= ρLL− αLC, (1b)
dB
dt
=
1
τI
I − αBC − 1
τB
B, (1c)
dP
dt
= ρP (2aP s(t)− 1)P − 1
τP
P, (1d)
dI
dt
= ρI (2aIs(t)− 1) I − 1
τI
I +
1
τP
P − αβIC. (1e)
Equation (1a) involves two proliferation terms of CAR T cells due to stim-
ulation by encounters with their target cells: either L(t), B(t) or I(t). The
parameter ρC > 0 measures the stimulation to mitosis after encounters with
CD19+ . cells disseminated throughout the whole body (mostly in the cir-
culatory system). The parameter ρβ = βρC , where 0 < β < 1, accounts for
the fact that immature B cells are located mostly in the bone marrow and
encounters with CAR T cells will be less frequent. The last term describes
the decay of CAR T cells with a mean lifetime τC .
In contrast to previous modelling approaches [25, 26, 28], we exclude
a death term in the CAR T cell compartment due to interaction with tar-
get cells. This is because the CAR T cells do not undergo apoptosis after
killing the target cell [30, 31]. Also, unlike in those models, there is no stan-
dard proliferation term proportional to the population of CAR T cells, since
these cells do not divide spontaneously [32]; instead their clonal expansion is
directly dependent on stimulation with the CD19 antigen.
Leukaemic cells [see Eq. (1b)] have a net proliferation rate ρL > 0 and die
due to encounters with CAR T cells. The parameter α measures the proba-
bility (per unit time and cell) of an encounter between CAR T and CD19+
cells. α and ρC will, in general, be different, due to possible asymmetric
cell interactions. Namely, if α > ρC , this would imply that CAR T cells
kill CD19+ target cells relatively faster than their own proliferation rate per
target cell encountered. In contrast, if α < ρC then, on average, the killing
process would be slower than the proliferation rate per target cell encoun-
tered by CAR T cells. For completeness, we will consider both cases via the
dimensionless parameter k = ρC/α. Other processes, encompassed by the
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term −αLC, would include target cell recognition, killing and detachment,
which are relatively much faster than the complete rendezvous kinetics [33].
Our model implicitly assumes that all T lymphocytes in the CAR product
have a similar cell killing capacity. This could be the case if both CD4+ T
helper cells and CD8+ T cells had a similar cell killing capacity, or if most
of the CAR product contains CD8+ cells. A more complex mathematical
framework should incorporate potential differences in killing capacity of these
two T lymphocytes [33, 34].
Equations (1c)-(1e), which involve B cells, consist of a compartment
for CD19− HSCs (i.e. P (t)) with an asymmetric division rate aP and a
differentiation rate 1/τP into a new compartment accounting for all of the
other CD19+ differentiated states of bone marrow progenitor B cells (Pro-B,
Pre-B, and immature cells) (embodied in I(t)). These cells are the source
of mature B cells. Since all cells in the I(t) compartment already express
the CD19+ antigen, they will be targets for the fraction of CAR T cells in
the bone marrow, namely βC(t). Finally, mature B cells B(t), which cannot
subsequently proliferate, are the terminal differentiation stage of these cells.
They have a mean lifetime τB, which is present in the last term of Eq. (1c).
The structure of the two haematopoietic compartments is similar to that
proposed in previous studies with haematopoiesis models [35]. In line
with those models, the signalling function s(t) can be assumed to be of the
saturable form s(t) = 1/ [1 + ks (P + I)], with ks > 0.
To describe CRS, let us define a variable Y (t) for the cytokines released
upon stimulation of CAR T cells by the antigens with rate ρY and cleared
with rate 1/τY . ICANS will be related to the number of CAR T cells infil-
trating the central nervous system (CNS), and is expected to be proportional
to the total number of CAR T cells, with a proportionality coefficient ρN ,
and removed at a rate 1/τN . Thus, toxicity can be described by the following
equations:
dY
dt
= ρYC (L+B)− 1
τY
Y, (1f)
dN
dt
= ρNC − 1
τN
N. (1g)
Notice that Eqs. (1a)-(1e) are uncoupled from Eqs. (1f)-(1g). A schematic
summary of the biological processes encompassed by our basic mathematical
model (1a-1g) is shown in Fig. 1.
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Figure 1: Processes included in the mathematical model (1). Ma-
ture B lymphocytes are generated from the CD19− haematopoietic stem
cells (HSCs) and through differentiation of immature CD19+ progenitors
with characteristic lifetimes τP and τI , respectively. CAR T cells are stim-
ulated when meeting CD19+ B cells (normal, leukaemic or immature) with
stimulation parameters ρC and ρβ, and undergo apoptosis with a lifetime τC .
leukaemic cells proliferate with a rate ρL. Both mature B and leukaemic
cells are destroyed via encounters with the CAR T cells with a killing effi-
ciency α. Cytokines are released with a rate ρY , which may result in acute
toxicities (cytokine release syndrome) and are cleared at a rate 1/τY . A
fraction of the CAR T cells disseminates and infiltrates the central nervous
system. Typical neurological toxicities induced by CAR T cells are immune
effector cell-associated neurotoxicity syndromes. Thick coloured arrows
describe different individual cell processes. Narrow coloured arrows depict
both release and degradation of chemical agents. Black double-headed arrows
indicate cell-cell interactions.
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Appendix A shows some mathematical results on the existence, unique-
ness and positiveness of the solutions of system (1a)-(1e).
2.2. Reduced mathematical models
Equations (1a)-(1e) exclude different biological facts such as heterogene-
ity in the CAR T-lymphocyte subpopulations, the differential expression of
the CD19 antigen over leukaemic and healthy B cells subclones, the role
of regulatory T-cells, etc. However, there are still many parameters to be
determined. The contribution of the bone marrow Eqs. (1d)-(1e) is to ac-
count for the generation of new B-cells. Hence, to capture their role while
simplifying the full system, we can compute the equilibria for Eqs. (1d)-(1e)
I =
1
τP kS
(
2aP τP ρP
1+τP ρP
− 1
)
1
τI
+ 1
τP
+ ρI
[
1− aI
aP
(
1 + 1
τP ρP
)]
+ αβC
≡ I0
1 + C/C50
, (2)
and assume (2) to hold for all time. This provides a suitable representation
of the contribution of immature B cells in the bone marrow to global disease
dynamics. Then, Eqs. (1a)-(1e) reduce to the set
dC
dt
= ρC (L+B)C +
ρCβI0
1 + C/C50
C − 1
τC
C, (3a)
dL
dt
= ρLL− αLC, (3b)
dB
dt
=
I0/τI
1 + C/C50
− αBC − 1
τB
B. (3c)
In the first weeks after CAR T injection, the main contribution to the
dynamics is the expansion of these cells and their effect on the healthy B and
leukaemic cells. Thus, we may neglect the contribution of the haematopoietic
compartments in Eqs. (3a) and (3c) to get
dC
dt
= ρC (L+B)C − 1
τC
C, (4a)
dL
dt
= ρLL− αLC, (4b)
dB
dt
= −αBC − 1
τB
B. (4c)
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The study of existence and uniqueness of solutions, together with the
stability of the critical points for both systems, are presented in Appendix
B and Appendix C.
2.3. Parameter estimation
B-cell lymphocyte lifetime τB is known to be about 5-6 weeks [47]. These
cells account for a variable fraction between 5% and 20% [48] of the total
lymphocyte number [49] leading to > 1011 B-lymphocytes in humans. In
this paper, since CAR T cells are injected after lymphodepleting treatment,
in most simulations we set the initial number of B-lymphocytes to be 2.5
×1010 to account for the effect of this treatment.
ALLs are fast-growing cancers with proliferation rates ρL of the order
of several weeks [35, 50]. Na¨ıve CD8+ T cells are quiescent, their mean
lifetime ranges from months to years, and they enter the cell cycle following
interaction with their antigen [51, 52]. These activated CD8+ T cells induce
cytolysis of the target cells and secrete cytokines such as TNF-α and IFNγ.
Following activation, most effector cells undergo apoptosis after two weeks,
with a small proportion of cells surviving to become CD8+ memory T cells
capable of longer survival [51]. Recent studies have reported longer survival
values of about one month [13]. Thus, we will take the mean lifetime τC of
CAR T cells to be in the range of 2-4 weeks.
To estimate the interaction parameter α we will use the fact that when
measured by flow cytometry or qPCR, CAR T cells in children treated for
ALL reached a maximum in vivo expansion at around 14 days [37], which
is a typical value observed in other clinical studies. Finally, the mitotic rate
ρC , related to the stimulatory effect of each encounter between T cells and
the CD19+ cells, will be taken to be proportional to α (ρC = kα), with
k ∈ (0.05, 2). The exact value would depend on the properties of the CAR
T product, but taking B +L initially to be around 1011 and using Eqs. (4a)
we obtain an initial exponential growth rate for CAR T cells of around k
day−1 , in line with values reported in other models (e.g in Ref. [29], the
authors obtained 0.89 day−1 from data).
The parameter values used in this paper are summarised in Table 1.
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Parameter Meaning Value Units Source
τB B-lymphocyte 30− 60 day [47]
lifetime
ρL Leukaemic growth rates 1/30− 1/60 day-1
τC Activated CAR T 14− 30 day [51, 13]
cell lifetime
ρC Mitotic stimulation (0.05− 2)× α day-1
of CAR T cells by × cell-1
CD19+ cells
α Killing efficiency ∼ 10−11 day-1 Estimated
of CAR T cells × cell-1 from [37]
k ρC and α ratio 0.05− 2 dimensionless Estimated and
compatible with
[29]
τI Immature bone marrow 2− 6 day [53, 54]
B cell lifetime
β Fraction of CAR T cells 0.01− 0.5 dimensionless [55]
in the bone marrow
Table 1: Relevant parameter values for model Eqs. (4)
3. Results
In this section, we present the results obtained from systems (3) and (4).
We first analyse (4):
3.1. Mathematical model (4) describes post CAR T cell injection dynamics
We first studied the dynamics of the system post-CAR T cell injection
numerically, as described by Eqs. (4). Figure 2 shows a typical example.
During the first two months of the simulation, CAR T cells expanded,
showing a peak at about two weeks post-injection, before their numbers sta-
bilised and began to decrease. Both the leukaemic and B-cell compartments
experienced a continuous decrease towards undetectable values representing
the dynamics of a patient without residual disease. The expansion of the
CAR T population was exponential, increasing by several orders of magni-
tude [see Figure 2(b)], in line with reported clinical experience and patient
datasets [13].
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Figure 2: Typical dynamics of leukaemic cell (red curve), B-cell
(blue curve) and CAR T cell (green curve) compartments according
to Eqs. (4). (a) Simulations for parameters α = 4.5× 10−11 day−1cell−1,
τC = 14 days, ρL = 1/30 day
−1, ρC = 0.25α, τB = 60 days and injected
cells C0 = 10
7 corresponding, to 5×105 cells per kg for a 20 kg child. Also,
L0 = 5× 1010 and B0 = 2.5× 1010, which correspond to typical values after
lymphodepleting chemotherapy. (b) Logarithmic plot of the CAR T cell
population.
3.2. The number of injected CAR T cells does not affect treatment outcome,
but the stimulation rate does
We next studied the dynamics of Eqs. (4) under different numbers of
injected CAR T cells. A typical example is displayed in Figure 3(a). The
change of one order of magnitude in the initial CAR T cell load resulted
in minor changes in the maximum expansion achieved (of around 6%). A
reduction in the time to peak expansion in silico of about 3 days was observed.
However, the persistence of CAR T cells was not affected by their initial load.
It has already been observed that when the number of CAR T cells seeded
is small, the therapy can fail [36]. We simulated in silico, and saw that the
effect of a reduction in the growth efficiency of the cells (the stimulation rate
ρC) and the dynamics were substantially affected [see Fig. 3]. A reduction in
the efficiency of stimulation in the CAR T cells led to a slower growth of this
population in silico, resulting in leukaemic cells reaching higher numbers
for almost two months without any clinical response.
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Figure 3: The number of injected CAR T cells does not affect
treatment outcome, but the stimulation rate does. (a) Dynamics
of leukaemic cells (red line), B-cells (blue line) and CAR T cells (green line)
according to Eqs. (4) for the virtual patient of Fig. 2 subject to injections
of 5× 105 cells/kg (solid lines), 15× 105 cells/kg (dashed lines) and 45× 105
cells/kg (dotted lines). (b,c) Dynamics for stimulation rates ρC = 0.25α
(solid line) and ρC = 0.05α (dotted lines). (c) CAR T cell expansion in log
scale.
3.3. Maximum expansion of CAR T cells in vivo and CRS
System (4) is amenable to finding useful analytical and semi-analytical
expressions, which are all derived in Appendix D.
At time tmax, which typically occurs within 2-4 weeks after injection of the
CAR T cells, a first maximum in their number, denoted by Cmax ≡ C(tmax),
is achieved during the expansion phase. The value of tmax can be calculated
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from the implicit relation
log
[
ρCτC
(
L0 e
ρLtmax +B0 e
− tmax
τB
)]
− α
∫ tmax
0
C(t)dt = 0. (5)
Furthermore, it is possible to estimate the maximum number of CAR T
cells Cmax, which is approximately given by
Cmax ' C0 + k
(
L0 +B0 − 1
ρCτC
)
, (6)
where C0, L0 and B0 are the initial conditions for the CAR T, leukaemic and
B cells (assumed to be positive), respectively. Thus, the maximum number
of CAR T cells that can be reached during the first expansion phase will be
related to the initial populations L0 and B0 multiplied by the ratio k. Note
also that, in practice, the contribution of C0 is much smaller than the second
term in Eq. (6) and can be ignored, suggesting that the initial number of
injected CAR T cells does not affect the peak, although it does contribute
in (5) when computing tmax. Both results (5) and (6) provide an analytical
justification of the numerical results discussed for Eqs. (4) in Section 3.2.
Explicit formulas for computing the leukaemic and B cell loads in patients
at time tmax can easily be obtained. These are given by
L(tmax) =
L0 e
(
ρL+
1
τB
)
tmax
ρCτC
(
B0 + L0 e
(
ρL+
1
τB
)
tmax
) , (7a)
B(tmax) =
B0
ρCτC
(
B0 + L0 e
(
ρL+
1
τB
)
tmax
) . (7b)
Alternatively, if L(tmax) and B(tmax) are available, together with L0, B0, τC
and τB, then parameters ρC and ρL can be estimated, which is relevant from
a clinical viewpoint.
Since toxicity, accounted for by Eqs. (1f) and (1g), depends on the maxi-
mum CAR T cell number, one would expect a smaller ratio k to lead to lower
toxicities. Figure 4 shows the linear dependence of the maximum number of
CAR T cells on ρC as obtained from simulations of Eqs. (4), which is well
approximated by Eq. (6). The above result points to a proportional relation
between the total leukaemic load and the severity of the CRS syndrome. In
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Figure 4: Dependence on ρC of the maximum number of CAR T
cells and the time tmax taken to achieve the maximum. Common
parameters for all plots are as in Figure 2: α = 4.5× 10−11 cell−1 day−1,
τC = 14 days, ρL = 1/30 day
−1, τB = 60 days and initial cell numbers C0
= 107 cells, B0= 2.5 × 1010 cells. (a) Maximum value number of CAR T
cells obtained for initial leukaemic loads of 5 × 1010 cells (red) and 2.5 ×
1010 cells as a function of ρC . Solid line indicates the results obtained from
Eqs. 4 and the dashed line the upper bound given by Eq. (6). (b) Time to
maximum value of CAR T cells for different leukaemic loads computed from
Eq. (5).
fact, a strong correlation between the severity of CRS and disease load at
the time of CAR T cell infusion has been noted in multiple clinical trials of
CAR T cell therapy of haematological malignancies [37, 38, 39, 40].
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Figure 5: CAR T cell persistence when varying its lifetime τC . Dy-
namics of the leukaemic cell (red), B-cell (blue) and CAR T cell (green)
according to model Eqs.(4). Solid and dashed curves correspond to τC = 14
days and τC = 30 days, respectively, with the rest of parameters and initial
data as in Figure 2.
3.4. CAR T cell persistence depends on the T cell mean lifetime
The recent clinical study [13] showed much longer persistence of the CAR
T cells when their mean lifetime was increased to τC = 30 days, larger than
the more common value τC = 14 days. We simulated the dynamics of Eqs.
(4) for both values of τC . An example is shown in Fig. 5. While the B-cells
and leukaemic cells exhibited similar behaviour, CAR T cells showed a
much longer persistence in line with the clinical observations.
3.5. CD19+ relapses could be a dynamical phenomenon
We performed simulations of Eq. (4) for longer timescales (with parame-
ters as in Fig. 2) and observed a long-time relapse (see Fig. 6) at about one
year after infusion, in what would be a CD19+ relapse. Leukaemic growth
continued for several months but finally there was an outgrowth of CAR T
cells after the relapse that was able to control the disease. This is an impor-
tant nonlinear dynamical phenomenon that could help explain some CD19+
relapses.
When B ∼ 0, as after CAR T cell expansion, Eqs. (4) become the well-
known Lotka-Volterra predator-prey mathematical model. That model gives
rise to periodic oscillations corresponding to ecological cycles that have been
14
Figure 6: CD19+ relapses could be a dynamical phenomenon. Long-
time dynamics of Eqs. (4) for leukaemic (red), B (blue) and CAR T (green)
cells in the time interval [0,600] days, displaying a CD19+ relapse as the result
of predator-prey type dynamics in silico. Parameters are as in Figure 2.
The shaded area indicates the time interval in which the disease would be
progressing without further interventions. Notice the subsequent emergence
of CAR T cells after the CD19+ cell relapse.
observed both in ecosystems [41] and in experimental models [42]. In our
present case, the period of the cycles would be related to the cancer relapse
time. This period has been previously described as showing a complex
dependence on a conserved quantity, K [43] (having in our case units of
s−1), and given by
K = αC − ρL log
(
αC
ρL
)
+ ρCL − 1
τC
log (ρCτCL) ∼ ρC (L0 +B0) . (8)
The conserved quantity K  1, can be approximated by the asymptotic
formula [44], which in our case yields the period L of oscillations
L(K) = ρCτC(L0 +B0)
ρL
+
1
ρL
log [ρCτC (L0 +B0)]
+ τC log
[
ρC (L0 +B0)
ρL
]
+O
(
logE
E
)
∼ ρCτC (L0 +B0)
ρL
. (9)
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Because of the approximations involved, Eq.(9) should only be taken as an
order-of-magnitude estimate for the cancer relapse time. However, it is
interesting that longer lifetimes of the CAR T cells resulted in longer relapse
times according to Eq. (9). This could be the reason why so few CD19+
relapses were observed in the recent trial [13], with τC = 30 days, much
longer than the more common value τC ∼ 14 days.
A very intriguing question is whether those relapses could resolve spon-
taneously due to the predator-prey type competition between the CAR T
and leukaemic cells. Owing to the long progression time, this could pass
unnoticed, since after progression, other therapeutic actions would be taken,
such as haematopoietic transplants, before allowing the CAR T to appear
again.
Although our simulations point to a potentially interesting scenario, the
model given by Eqs. (4) is not good for studying long-term phenomena. One
of the missing biological processes in Eqs. (4) is the potential contribution
of B-cell production in the bone marrow from CD19− haematopoietic stem
cells to the maintenance of a pool of CAR T cells. Thus, to get a more
realistic insight into the dynamics, we simulated Eqs. (3) for the same
virtual patients and biologically reasonable parameters β = 0.1, τI = 6 days
(see Table 1) and different values for the production of B cells in the bone
marrow embodied by I0.
One set of examples is shown in Figure 7. The more realistic model given
by Eqs. (3) still presents first relapse at a time independent of the choice
of the flux I0. However this parameter influenced the post-relapse dynamics.
For values of I0 smaller than approximately 10
7 cells/day, which is the typical
number of injected CAR T cells [36], there were no substantial changes in
the dynamics with subsequent relapses following a periodic pattern. Larger
values of I0 led to relapses of B cells before the relapse of leukaemic cells and
later of CAR T cells. Also, the relapse dynamics were in line with damped
oscillations, with both leukaemic and CAR T cell relapses having smaller
amplitudes. Interestingly, our model Eqs. (3) predict that a significant
increase of B cells could be used as a potential clinical biomarker indicative
of subsequent cancer relapse.
3.6. CAR T cell reinjection may allow the severity of relapse to be controlled
In the framework of our modelling approach leukaemia relapses would
be transient. However, the long potential duration of such relapses would
require further intervention to prevent patients from suffering undesirable
16
Figure 7: Long-time dynamics of virtual patients predicted by
Eqs. (3). Parameters are α = 4.5 × 10−11 cell−1 day−1, β = 0.1, τC = 14
days, τB = 60 days, ρL = 1/30 day
−1, ρC = 0.25α, C50 = 109 cells, τI = 6
days. The subplots show the dynamics of the leukaemic cell (red), B-cell
(blue) and CAR T cell (green) compartments. (a) Case I0 = 10
7 cell day−1.
(b) Case I0 = 3× 108 cell day−1, (c) Case I0 = 5× 108 cell day−1.
harm during such periods. An interesting question is whether it would be
possible to control these recurrences by acting on the leukaemia by rein-
jecting CAR T cells , and what the appropriate timings and doses for that
intervention would be.
Using the mathematical model (3), we simulated the reinjection of C =
17
107 CAR T cells at different times: before relapse (t = 300 days), at relapse
(t = 360 days), and after relapse (t = 415 days) and compared the outcome
with the case without reinjection. An example is shown in Figure 8(a,b).
Significant reductions of both the peak leukaemic cell number and re-
lapse duration were obtained, the best results being when reinjection was
performed on relapse. Thus, our in silico results suggest that the early rein-
jection of CAR T cells in a CD19+ B-leukaemia relapse could reduce disease
load and help in early control of the disease. This has interesting implications
since, after relapse is detected, CAR T preparation requires blood extrac-
tion, apheresis, T cell modification and expansion ex vivo, and finally patient
infusion. In clinical practice this process takes from three to six weeks.
From the practical point of view, a possibility for increasing the speed of
action after leukaemic cell identification would be to freeze and keep some
of the CAR T cells initially obtained so that they could be reinjected and
aid in early control of the disease.
We also studied the effect of the number of CAR T cells injected at the
optimal time. An example is shown in Figure 8(c,d). The effects of a very
small infusion of C = 105 cells are compared with those of a more standard
dose of C = 107 cells. The number of T cells injected affected the outcome.
This was different from our previous observation that the number of CAR T
cells injected initially did not affect the treatment outcome. The reason is
that, initially, there are many targets, both leukaemic and B cells, allowing
for a huge expansion of the CAR T population. However, on relapse, the
target population is smaller and a larger initial number of CAR T cells helps
in making the expansion process faster.
3.7. Model (3) predicts a scenario leading to zero leukaemic cells
The analysis of the non-negative equilibrium points of system (3), set out
in Appendix C, shows the possibility of reaching L = 0 after starting with
a non-zero leukaemic cell population. Using the parameters given in Table
1, we observe that there exist ranges for the ratio k and the bone marrow
B cell production I0 where one of the equilibrium points, P3 (a focus), is
asymptotically stable for different values of α. Hence, one of its associated
eigenvalues will be real (see Figure C.12 in Appendix C) while the other
two eigenvalues will be complex conjugate (see Figure C.13 in Appendix C).
Figure 9 illustrates an example with different initial conditions and the same
set of parameters for them. It should be pointed out that in all cases shown
in Figure 9, both the CAR T and the B cells remain at non-zero levels (of the
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Figure 8: CAR T cell reinjection may allow severity of relapse to
be controlled. Simulations of Eqs.(4) for parameter values α = 4.5× 10−11
cell−1 day−1, β = 0.1, τC = 14 days, τB = 60 day, ρL = 1/30 day−1, ρC =
0.25α, C50 = 10
9 cells, τI = 6 days, and I0 = 2 × 105 cell day−1. All
subplots show the dynamics of leukaemic (red) and CAR T (green) cells
upon reinjection of CAR T cells. Cases (a) and (b) display the dynamics of
(a) leukaemic and (b) CAR T cells, respectively, for doses of C = 107 cells
administered at times: t = 300 days (dash-dot line), t = 360 days (dotted
line) and t = 415 days (dashed line) in comparison with the dynamics without
reinjection (solid line). Subplots (c) and (d) illustrate the combined dynamics
of leukaemic and CAR T cells after reinjection of: (c) C = 105 cells and (d)
C = 107 cells at t = 360 days.
order of 5 × 108 and 109, respectively) when the leukaemic cell population
effectively becomes extinct (L < 1.)
These results are interesting as they suggest that there is a range of
biologically relevant parameters where the cancer may eventually disappear.
Our simulations indicate that the larger I0, k and α, the more likely it is that
L = 0 can be reached. In particular, if I0 is increased, this would imply
higher production of both B and CAR T cells, due to the contribution of
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Figure 9: Routes to leukaemic cell extinction. Phase portrait of sys-
tem (3) showing three orbits with different initial conditions ( coloured dots)
that lead to leukaemic extinction. Parameters for all orbits are α = 5×10−11
cell−1 day−1, β = 0.1, τC = 20 days, τB = 40 day, ρL = 1/45 day−1,
ρC = 0.7α, C50 = 10
9 cells, τI = 2.4 days, and I0 = 2× 108 cell day−1.
immature B cells from the bone marrow, resulting in a greater chance of
eradicating the leukaemic cells. This scenario provides another proof of the
concept that the mathematical model put forward here can be useful in the
clinical setting and may trigger new exploratory pathways.
3.8. Sensitivity analysis
A sensitivity analysis was carried out to identify the model parameters
with the greatest influence on the equilibria for CAR T, leukaemic and
B cells are I0, α and k. To do so, we calculated the first-order sensitivity
coefficient using Sobol’s method [57] to measure the fractional contribution
of a single parameter to the output variance. Using a priori information on
the parameters, we defined the distribution functions in the table shown in
Figure 10. We generated a set of parameters of size 1000 to calculate the
sensitivity indices. The results of the sensitivity analysis of Eqs. (3) are
shown in Figure 10.
The results show that the parameters with the greatest influence on the
solutions for CAR T, leukaemic and B cells are k, α, τC and I0. However,
their impact varies depending on the specific cell compartment and time.
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Figure 10: Sensitivity analysis of system (3) to identify the influence of the
model parameters on the solutions for (a) CAR T, (b) leukaemic and (c) B
cells. The parameter ranges studied and distributions used are displayed in
the lower-right table.
For CAR T cells, k and τC are the most significant during the first four
months after injection. For longer times, I0 becomes the most important.
For leukaemic cells, k and α are the most influential parameters, both during
the first weeks of the CAR T cell treatment and later during relapse. For
healthy B cells, k and α are the most relevant parameters during the first
weeks, but later on, on relapse, I0 also becomes important. Such parameter
dependences are also suggestive in order to target specific mechanisms that
would allow partial control over them.
4. Discussion
Cancer immunotherapy with CAR T cells is a promising therapeutic op-
tion already available for B cell haematological cancers. There has been a
growing interest in the mathematical descriptions of immunotherapy treat-
ments in cancer, particularly aimed at CAR T cells [25, 26, 28], but none of
them have addressed the specificities of CAR T-based immunotherapies for
the case of acute lymphoblastic leukaemias (ALL) on the light of available
clinical experience.
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In this work, we put forward a mathematical model incorporating the
main cell populations involved in the growth of ALL. The model included
not only leukaemic clones and CAR T cells, but also the haematopoietic
compartment that would be responsible for the persistence of CAR T cells
by the continuous generation of CD19+ progenitors from CD19− stem cells.
One simplified version of the full model already allowed us to describe the
clinical evolution of B ALL in the first months after CAR T injection yield-
ing explicit formulas of clinical added value such as the maximum number
of CAR T cells that can be reached. Also, it provided a rational support to
several clinical observations. Interestingly, the model predicted the possibil-
ity of CD19+ relapses being dynamical phenomena resembling predator-prey
oscillations. The more complex mathematical models were used to confirm
this dynamic and to further give support for therapeutically rechallenging
the leukaemia with CAR T cells in CD19+ relapses.
Although our model, which includes essential components driving the
CAR T cell and leukaemic cell dynamics, is shown to provide a description
of the response to treatments, there are several limitations in extending our
analysis to longer times and to the study of resistances. First of all, we did not
study the case of CD19− relapses. That study would require a different type
of modelling in line with previous mathematical frameworks accounting for
the development of other types of resistances under the evolutive pressure
of treatments [45]. Also, our description of CD19+ relapses was based on
a continuous model, that is not designed to faithfully capture the regime
where the numbers of predators (CAR T cells) and prey ( leukaemic and
B cells) are low. It has been discussed how in those scenarios the situation
is significantly more complex and may require different types of approaches,
such as those based on stochastic birth-death processes or even fully discrete
models accounting for different body compartments. However, the fact that
the bone marrow compartment would provide a continuous flux of B cells
leading to the maintenance of a pool of activated CAR T cells, may keep the
system out of the very low densities that could make the continuous model
fail.
B-cell lymphomas are usually treated with rituximab to provide a perma-
nent lymphodepletion also affecting HSC. Although lymphomas are different
diseases, it is interesting to note that CAR T cells would be expected to
persist for shorter times in that scenario due to the lack of continuous stim-
ulation for maintenance of a pool of these cells in the bone marrow. Thus,
it is expected that treatments would be less effective for these cancers .
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It is interesting to point out that in homeostasis there is a population of
T cells, the T regulators (Tregs), that control the total number of T cells and
have a role in limiting autoimmune processes. We did not incorporate Tregs
in our mathematical description. This could be a good approximation for the
first weeks of the CAR T cell expansion because the initial lymphodepletion
also affects Tregs. However, after the first 3-4 weeks, this population will be
able to expand again and has an effect on a faster reduction of the total CAR
T cell load. There is not much data available on the dynamics of Treg cells
and their reconstitution after the CAR T cell peak. We plan on accounting
for this population in future works.
The results obtained using the reduced mathematical model show that
the number of CAR T cells initially injected does not affect the subsequent
dynamics. Since at the outset CAR T cells do have a huge in vivo target
pool, including leukaemic and healthy B cells allowing them to expand, even
small doses of properly functioning immune cells would lead to a response.
Thus, according to our modelling approach, it may be better to store (freeze)
part of the cells generated so that they could be ready for later leukaemia
rechallenging in case of a CD19+ relapse. There, the combination of a fast
action after the detection of the disease and the injection of a substantial
number of CAR T cells would be clinically relevant according to our mathe-
matical model-based predictions. The reason is that a prompt action would
allow both for a reduced growth of the disease and for a smaller toxicity of
the disease, thus reducing risks for the patient such as CRS and ICANS.
The rationale behind the injection of larger CAR T loads on relapse is that
the target population would be smaller in general than at the start of the
treatment. Moreover, our model implies that a periodic treatment with CAR
T cells to avoid relapse would be quite ineffective, since they would not be
expected to expand well unless there is a substantial target population.
Our mathematical model allowed us to obtain an estimate for the very
relevant parameter of the relapse time, that would be the optimal time to
perform the re-injection of CAR T cells. The estimation obtained by Eq. (9)
shows that the relapse time depends on the parameters related to CAR T
cells (ρC and τC), the growth rate ρL of leukaemic cells and their density at
the beginning of treatment. In the framework of our continuous model all
leukaemias experience a relapse, however longer relapse times may correspond
in some simulation runs to leukaemias having intermediate densities that are
unrealistically low for very long times. Thus, we may expect that leukaemias
with quite long relapse times, according to our modelling approach, would
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never relapse.
We may act therapeutically on ρC and τC by designing CAR T cells with
higher stimulation ratios and longer persistence. However, it is important
to note that the first parameter would be expected to influence the initial
treatment toxicity (CRS and ICANS), thus probably, increasing the second
would be a better option, perhaps by increasing the fraction of CD8+ mem-
ory T cells in the CAR T cell pool. Contradictory evidence has been found
in this regard, although in this case the endpoint to consider would be the
number of CD19+ leukaemia relapses.
One of the most impactful findings in this research was the very relevant
role of the flux of generation of CD19+ progenitors from CD19− haematopoi-
etic stem cells, I0. Although these stem cells are known to be a very small
population (typically around 1% of all cells in the bone marrow), what mat-
ters most is the flow into the compartment of B-cells. We have recently
constructed a model of B-cell lymphopoiesis based on flow-cytometry data
that can provide typical populations in equilibrium [46] but the dynamics
are difficult to estimate since what is most relevant is what the flow of
progenitors would be when the CD19+ compartment is empty. We are now
collecting data on bone marrow reconstitution after haematopoietic stem cell
transplants in order to estimate these parameters and have more precise esti-
mates of I0. Our finding also opens the interesting possibility of considering
the pharmacological stimulation of the process of stem cell asymmetric divi-
sion and differentiation. This would lead to an increase in I0 and thus raise
the possibility of cancers being completely removed.
Our mathematical model also allows us to pose another interesting hy-
pothesis. B-ALL is a field where substantial progress has been made by
designing initial intensive treatment regimes combining different types of cy-
totoxic chemotherapies. On the basis of our mathematical model, and leaving
aside the important economic costs, one would expect that substantially less
aggressive chemotherapy regimes could be quite effective after CAR T cell
injection to eliminate the residual disease (mainly by greatly reducing the
ρC parameter). This strategy would also be beneficial to control CD19
−
relapses. In this case one should balance the side effects of current protocols
versus a combination of CAR T cells with a reduced chemo infusion. The
main limitation of this approach would be the sustained B-lymphodepletion
provoked by the immunotherapy treatment, but one can envision autologous
B stem cell transplants after in vitro treatment with CAR T cells to select
for CD19− HSCs.
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In conclusion we have put forward a mathematical model describing the
response of acute lymphoblastic leukaemias to the injection of CAR T cells.
Our theoretical framework provided a mechanistic explanation of the obser-
vations reported in different clinical trials. Moreover, it also predicted that
CD19+ leukaemia relapses could be the result of the competition between
leukaemic and CAR T cells in an analogous fashion to predator-prey dy-
namics. As a result, the severity of relapses could be controlled by early
rechallenging of the leukaemia with previously stored CAR T cells.
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Appendix A. Basic properties of the complete mathematical model:
system (1)
We state the following proposition:
Proposition 1. For any non-negative initial data (C(0), L(0), B(0), P (0),
I(0)) and all parameters of the initial value problem given by Eqs. (1a)-(1e)
being positive, the solutions for C(t), L(t), B(t), P (t), and I(t) exist for all
t > 0, are unique and non-negative.
Proof. We first prove the non-negativity of the solutions. Let F = F(x)
denote the vector field representing the right-hand-side of Eqs. (1a)-(1e),
with function x ≡ (C,L,B, P, I). Also, let nj denote the outward normal unit
vector to plane xj = 0, with j = 1, 2, . . . , 5. That is, n1 = (−1, 0, 0, 0, 0) and
analogously for other nj. Consider the scalar products of the ODE system
dx
dt
= F(x) with each nj and assume that the initial data (C(0), L(0), B(0),
P (0), I(0)) are positive. Then, dx
dt
·n1 = F · n1 = 0, dxdt ·n2 = F · n2 = 0 and
dx
dt
·n4 = F · n4 = 0 at hyper-surfaces C = 0, L = 0 and P = 0, respectively.
Then, the hyper-surfaces C = 0, L = 0 and P = 0 are invariant.
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Next, dx
dt
·n5 = F · n5 = − 1τP P ≤ 0 at plane I = 0. Finally, dxdt ·n3 =
F · n3 = − 1τI I ≤ 0 at plane B = 0. Hence, pieces of hyper-surfaces {I =
0} ∩R5+,0 and {B = 0} ∩R5+,0 are semipermeable inward R5+,0.
As a result, R5+,0 is a positively invariant domain for Eqs. (1a)-(1e).
Therefore, non-negativity of solutions (C,L,B, P, I) follows.
Since all parameters in Eqs. (1a)-(1e) are finite and the right-hand-
side of the system is a continuous function in (C,L,B, P, I) in the domain
R5+,0, existence of solutions of Eqs. (1a)-(1e) follows from the Cauchy-Peano
theorem. Moreover, as the partial derivatives of the right-hand side of the
system are also continuous and bounded in R5+,0, uniqueness follows from the
Picard-Lindelo¨f theorem. This completes the proof.
Appendix B. Basic properties of the reduced mathematical model:
system (4)
Proposition 2. For any non-negative initial data (C0, L0, B0) and all the
parameters of the model being positive, the solutions to Eqs. (4) exist for
t > 0, are non-negative and unique.
Proof. The proof mimics the steps of the proof of Proposition 1 so the
repetitive details are omitted.
Before delving into the analysis of system (3), it is convenient to first
understand the dynamics of a simplified version of (3) given by Eqs. (4). We
begin by calculating the fixed points and determining their stability. These
are the points P1 = (0, 0, 0) and P2 = (
ρL
α
, 1
ρCτC
, 0).
To analyse the stability of these points, we calculate the Jacobian matrix
of Eqs. (4):
J(C,L,B) =
ρC(L+B)− 1τC ρCC ρCC−αL ρL − αC 0
−αB 0 −αC − 1
τB
 .
• Equilibrium point P1 = (0, 0, 0). The Jacobian matrix is
J(P1) =
 − 1τC 0 00 ρL 0
0 0 − 1
τB
 ,
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and the eigenvalues are λ1 = 1/τC , λ2 = ρL and λ3 = −1/τB. Thus, P1
is a saddle point and therefore, an unstable equilibrium point.
• Equilibrium point P2 = (ρLα ,
1
ρCτC
, 0).
If we make the following linear change of coordinates x = C − ρL/α,
y = L− 1/ρCτC and z = B we move the point P2 to the origin and the
system (4) becomes
dx
dt
=
ρCρL
α
(y + z) + ρC(y + z)x, (B.1)
dy
dt
= − α
ρCτC
x− αxy, (B.2)
dz
dt
= −(ρt + 1
τB
)z − αxz. (B.3)
The Jacobian matrix for this point is:
J(P2) =
 0 ρCρLα ρCρLα− α
ρCτC
0 0
0 0 −ρL − 1τB
 .
The eigenvalues of the matrix are λ1,2 = ±
√
ρL
τC
i and λ3 = −ρL − 1τB .
Since λ1,2 are imaginary eigenvalues, this point is a non-hyperbolic
point. This means that for the linearised system, P2 is a centre, but
it is not possible to conclude its stability for the nonlinear system.
On the other hand, since λ3 < 0, P2 possesses a local stable manifold
corresponding to that eigenvalue. Thus, P2 has a local centre manifold
(corresponding to the eigenvalues λ1,2) of dimension 2 and a local stable
manifold (corresponding to the eigenvalue λ3).
Since λ3 is negative, all the orbits starting near the equilibrium point
approach the centre manifold. It is straightforward (although some-
what tedious) to verify that the centre manifold is given by z =
h(x, y) = 0. So, the qualitative behaviour of the local flow can then
be determined from the flow of the following system on the centre
manifold z = 0:
dx
dt
=
ρCρL
α
y + ρCxy, (B.4)
dy
dt
= − α
ρCτC
x− αxy. (B.5)
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Making the following change of variables
t→ α
ρCτC
√
at, y → √ay,
where a = ρ2CρLτC/α
2, b = ρ2CτC/α and m = ρCτC , we obtain
dx
dt
= y +
b
a
xy,
dy
dt
= −x− m√
a
xy.
(B.6)
If we introduce polar coordinates, defined by
x = r cos θ, y = −r sin θ,
system (B.6) becomes
r˙ = R(r, θ),
θ˙ = 1 + Θ(r, θ),
(B.7)
where
R(r, θ) = − b
a
r2 cos2 θ sin θ − m√
a
r2 sin2 θ cos θ,
Θ(r, θ) =
b
a
r cos θ sin2 θ − m√
a
r sin θ cos2 θ.
(B.8)
Thus, we can derive an equation for r as a function of θ through the
differential equation
dr
dθ
= −
b
a
r2 cos2 θ sin θ + m√
a
r2 sin2 θ cos θ
1 + b
a
r cos θ sin2 θ − m√
a
r sin θ cos2 θ
. (B.9)
In a neighbourhood of r = 0,(
1 +
b
a
r cos θ sin2 θ − m√
a
r sin θ cos2 θ
)−1
= 1 +
m√
a
r sin θ cos2 θ
− b
a
r cos θ sin2 θ +O(r2).
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As a result, for small r we obtain the following expression as the Taylor
series of Eq. (B.9):
dr
dθ
= −
[
b
a
cos2 sin θ +
m√
a
sin2 θ cos θ
]
r2
+
[
b2
a2
cos3 θ sin3 θ − m
2
a
sin3 θ cos3 θ +
bm
a
√
a
sin4 θ cos2 θ
]
r3
−
[
bm
a
√
a
cos4 θ sin2 θ
]
r3 +O(r4).
Now, we use the method of averaging to carry out a change of variable
with the effect of reducing the non-autonomous differential equation to
an autonomous one. Let the transformation be
r = ρ+ g1(θ)ρ
2 + g2(θ)ρ
3, (B.10)
with
g′1(θ) = −
b
a
cos2 θ − m√
a
sin2 θ cos θ,
g′2(θ) =
(
b2
a2
− m
2
a
)
cos3 θ sin3 θ +
bm
a
√
a
sin4 θ cos2 θ − bm
a
√
a
cos4 θ sin2 θ,
and formally arrive at the equation
dρ
dθ
= 0. (B.11)
At this point, we are in a position to apply the Centre Theorem of
Lyapunov (see for instance [56]) which ensures that when dr/dθ can
formally be transformed to zero, the equilibrium point is a centre.
Thus, the origin is a centre and so the equilibrium point P2 is also a
centre.
It is also possible to find a Lyapunov function of the system (B.6) as
V (x, y) =
a
b
x+
√
a
m
y − a
2
b2
log
(
1 +
b
a
x
)
− a
m2
log
(
1 +
m√
ay
)
, (B.12)
and V˙ = 0, ∀(x, y) ∈ R2. As R2+ is a positively invariant manifold, all the
orbits go periodically around P2.
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Figure B.11: (Left) An orbit of the phase portrait of system (4). (Right) An
orbit of the phase portrait of system (3). The parameters used to calculate
such orbits are given in Table 1.
An orbit of the phase portrait for a solution of system (4) is shown in
Fig. B.11 (Left).
Finally, let (C(t), L(t)) be an arbitrary solution of (4) for B = 0, and
denote its period by L > 0. It is possible to calculate the time average
of variables C and L (that is, the number of CAR T and leukaemic cells,
respectively). Dividing the first equation of (4) by C, the second by L and
integrating from 0 to L and using the fact that the solutions are periodic, we
get
0 = logC(t)
∣∣L
0
= ρC
∫ L
0
L(t)dt− 1
τc
L, (B.13)
and
0 = logL(t)
∣∣L
0
= ρLP − α
∫ L
0
C(t)dt. (B.14)
Hence
1
L
∫ L
0
C(t)dt =
ρL
α
, (B.15)
1
L
∫ L
0
L(t)dt =
1
ρCτC
, (B.16)
whose values are equal to the equilibrium point P2 for the two first coordi-
nates.
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Appendix C. Basic properties of the reduced mathematical model:
system (3)
We have the following proposition for system (3), which is similar to the
previous propositions for systems (1) and (4), and therefore details of the
proof are omitted:
Proposition 3. For any non-negative initial data (C(0), L(0), B(0)) and
all parameters of the initial value problem given by Eqs. (3a)-(3c) being
positive, the solutions for C(t), L(t) and B(t) exist for all t > 0, are unique
and non-negative.
On the other hand, the non-negative equilibrium points of system (3) are:
• Equilibrium point P1 = (C∗1 , L∗1, B∗1) =
(
0, 0, τB
τI
I0
)
.
• Equilibrium point P2 is given by
P2 = (C
∗
2 , L
∗
2, B
∗
2)
=
ρL
α
,
1
ρCτC
− I0(τB + β (1 + ρLτB)τI)
(1 + ρLτB)
(
1 + ρL
αC50
)
τI
,
I0τB
(1 + ρLτB)
(
1 + ρL
αC50
)
τI

where we assume that
1
ρCτC
>
I0(τB + β (1 + ρLτB)τI)
(1 + ρLτB)
(
1 + ρL
αC50
)
τI
. (C.1)
• P3 = (C∗3 , L∗3, B∗3) =
(
C∗3 , 0,
1
ρCτC
− βI0
1+C∗3/C50
)
where C∗3 is given by
C∗3 = −
C50
2
(
1 +
1
ατBC50
− ρCβI0τC
)
+
C50
2
√(
1 +
1
ατBC50
− ρCβI0τC
)2
+
4ρCI0τC
αC50
(
β
τB
+
1
τI
− 1
ρCI0τCτB
)
with the following conditions holding
β
τB
+
1
τI
>
1
ρCI0τCτB
,
1
ρCτC
>
βI0
1 + C∗3/C50
. (C.2)
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• P4 = (C∗4 , L∗4, B∗4) =
(
C∗4 , 0,
1
ρCτC
− βI0
1+C∗4/C50
)
where C∗4 is given by
C∗4 = −
C50
2
(
1 +
1
ατBC50
− ρCβI0τC
)
− C50
2
√(
1 +
1
ατBC50
− ρCβI0τC
)2
+
4ρCI0τC
αC50
(
β
τB
+
1
τI
− 1
ρCI0τCτB
)
with the following conditions being satisfied
1 +
1
ατBC50
< ρCβI0τC ,
β
τB
+
1
τI
<
1
ρCI0τCτB
,
1
ρCτC
>
βI0
1 + C∗4/C50
. (C.3)
Regarding the study of the stability of the equilibrium points, we obtain
the following conclusions:
• The eigenvalues of P1 are
λ1 = ρL, λ2 = − 1
τB
, λ3 =
I0ρCτBτC − τI + I0βρCτCτI
τCτI
and therefore P1 is an unstable point (saddle point).
• Using the Routh-Hurwitz criterion, it follows that P2 is asymptotically
stable for any positive I0 value, assuming that condition (C.1) is satis-
fied. Since for I0 = 0 we obtain the system (4), it means that a small
perturbation of I0 = 0, i.e. I0 = ε, with ε sufficiently small, will trans-
form the centres obtained in the system (4) into asymptotically stable
foci. Therefore, I0 = 0 is a bifurcation point since for this value the
type of stability changes, and we obtain a Hopf bifurcation. An orbit
of the phase portrait for a solution of system (3), for this case, is shown
in Fig. B.11(right).
• Carrying out a stability study, in a general way, for both P3 and P4 is
very complex, so we have performed a study within the confines of the
parameter range collected in Table 1, which are biologically relevant.
We have observed that for all parameters in Table 1, P4 has at least
one negative component, and thus we do not consider such biologically
unfeasible scenarios.
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Figure C.12: Values of the sign of eigenvalue λ1 for different values of I0
and k for (a) α = 4.5 · 10−11 (b) α = 10−10 (c) α = 3 · 10−11. The orange
shaded region corresponds to eigenvalue λ1 positive.
Figure C.13: Pseudocolour plots of the real and imaginary parts of P3 for
different values of I0 and k for (a) α = 4.5 · 10−11 and (b) α = 10−10
There exist parameters for P3 for which the components C
∗
3 , L
∗
3, and B
∗
3
are all positive and correspond to a point that is an asymptotically stable
focus. Figure C.12 shows the region where the real eigenvalue, say λ1, is
negative or positive, as a function of I0 and k and for different values of α.
Figure C.13 depicts all the eigenvalues of P3 for different values of I0, k and
α. As can be seen, the real part of the complex eigenvalues λ2 and λ3, is
always negative. On the other hand, the real eigenvalue λ1 changes its sign
for different values of I0, k and α. Then, the stability and instability of P3
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is given by the sign of λ1.
Appendix D. Analytical formulae for system (4)
Lemma 1. Let L0 and B0 denote the initial conditions for the leukaemic
and B cells, which are assumed to be positive numbers. The exact positive
solutions of model Eqs. (4) for the leukaemic and B cells, denoted by L =
L(t) and B = B(t), respectively, satisfy for all t > 0
L(t)
B(t)
=
L0
B0
exp
[(
ρL +
1
τB
)
t
]
. (D.1)
Proof. The positive solutions to Eqs. (4b) and (4c) are given, respectively,
by
L(t) = L0 exp
(
ρLt− α
∫ t
0
C(s)ds
)
, (D.2a)
B(t) = B0 exp
(
− t
τB
− α
∫ t
0
C(s)ds
)
. (D.2b)
Formula (D.1) easily follows from Eqs. (D.2a) and (D.2b) by calculating their
quotient.
Proposition 4. Let tmax denote the time at which a local positive maximum
of the CAR T cell solution C = C(t) to Eq. (4a) occurs. Then, the positive
solutions to Eqs. (4b) and (4c) at t = tmax satisfy
L(tmax) =
L0 e
(
ρL+
1
τB
)
tmax
ρCτC
(
B0 + L0 e
(
ρL+
1
τB
)
tmax
) , (D.3a)
B(tmax) =
B0
ρCτC
(
B0 + L0 e
(
ρL+
1
τB
)
tmax
) , (D.3b)
where L0 and B0 are the initial conditions for the leukaemic and B cells,
assumed to be positive numbers.
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Proof. If C = C(t) has a local positive maximum at t = tmax, then
dC
dt
=
0 at t = tmax. Using Eq. (4a), we get ρC (L(tmax) +B(tmax)) − 1τC = 0.
Thus, L(tmax) + B(tmax) =
1
ρCτC
. Combining this expression with the above
formula (D.1) evaluated at t = tmax, Eqs. (D.3) follow.
Proposition 5. Let tmax denote the time at which a local positive maximum
of the CAR T cell solution C = C(t) to Eq. (4a) occurs. Then tmax can be
calculated from the implicit relation
log
[
ρCτC
(
L0 e
ρLtmax +B0 e
− tmax
τB
)]
− α
∫ tmax
0
C(t)dt = 0 (D.4)
Proof. Combining (D.2a) and (D.2b), and setting t = tmax, we get
L(tmax) +B(tmax) =
(
L0 e
ρLtmax +B0 e
− tmax
τB
)
e−α
∫ tmax
0 C(s)ds. (D.5)
Using the fact that L(tmax)+B(tmax) =
1
ρCτC
, Eq. (D.5) can be finally written
as (D.4).
Proposition 6. Let Cmax be the value of the local positive maximum of the
CAR T cell solution C = C(t) to Eq. (4a), occurring at time tmax. Then,
Cmax = C0 +
ρC
α
(
L0 +B0 − 1
ρCτC
)
− 1
τC
∫ tmax
0
C(s)ds
+
ρLρC
α
∫ tmax
0
L(s)ds− ρC
ατB
∫ tmax
0
B(s)ds . (D.6)
Proof. We first combine Eqs. (4) in the form
1
ρC
dC
dt
+
1
α
(
dL
dt
+
dB
dt
)
= − 1
ρCτC
C +
ρL
α
L− 1
ατB
B. (D.7)
Upon integration, we get
C(t) = C0 − ρC
α
(L(t) +B(t)− L0 −B0)
− 1
τC
∫ t
0
C(s)ds+
ρLρC
α
∫ t
0
L(s)ds− ρC
ατB
∫ t
0
B(s)ds . (D.8)
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Setting t = tmax and using L(tmax) + B(tmax) =
1
ρCτC
in (D.8), the result
follows.
Numerical evaluation of the three integrals on the right-hand side of
(D.8) reveals that, for the parameters shown in Table 1, each is smaller (by
at least one order of magnitude) than the second term (note that there is also
partial cancellation among the three integrals). Hence, we may approximate
(D.8) by (6).
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